Media and Communications

News

Corporate

Monday, March 31, 2014
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE® Patent

JERUSALEM--(BUSINESS WIRE)--Mar. 31, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company’s COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”). The 808 patent expires on September 1, 2015 and claims a process for manufacturing the active ingredient of Teva’s relapsing-remitting multiple sclerosis (RRMS) product, C Read More »

Thursday, March 13, 2014
Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event – Announce Collaboration on New National Clinical Drug Development Initiative and Dementia Research

Teva to collaborate on new UK Government-led clinical drug development initiative The initiative creates a single point of entry into the UK health system reducing complexity and increasing speed, efficiency of running drug development programs Teva plans to invest approximately $20 million in clinical development in the UK and up to an additional $1 million for basic research into dementia – one of the critical global healthcare issues facing society today Read More »

Monday, February 24, 2014
Teva to Present at the Citi 2014 Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Citi 2014 Global Healthcare Conference in New York, NY. Dr. Michael Hayden, President of Global R&D & CSO will present on Wednesday, February 26, 2014 at 1:50 PM EST   What: Teva Presentation at the Citi 2014 Global Healthcare C Read More »

Monday, February 24, 2014
Teva Files 2013 Annual Report on Form 20-F

JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s com Read More »

Friday, February 21, 2014
Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe

Innovative new inhaler for asthma and COPD patients JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for DuoResp® Spiromax® (budesonide & formoterol fumarate dihydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appr Read More »

Friday, February 21, 2014
Teva Completes Tender Offer for NuPathe Inc. Shares

Merger Expected to Close Today 80% of Shares Tendered JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) today announced the successful completion of the tender offer (the “Offer”) by Train Merger Sub, Inc. (“Merger Sub”), a wholly-owned subsidiary of Teva, for all of the outstanding shares of common stock of NuPathe Inc. (Nasdaq:PATH) (“NuPathe”) at a price of $3.65 per share in cash and the right to receive contingent cash consideration payments of up to $3.15 Read More »

Thursday, February 13, 2014
Teva Announces Full FDA Approval of SYNRIBO® (Omacetaxine Mepesuccinate) for Injection

24-Month FDA Post Marketing Commitment Completed JERUSALEM--(BUSINESS WIRE)--Feb. 13, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA. SYNRIBO is indicated for adult patients with chr Read More »

Tuesday, January 28, 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL

New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE®. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple Read More »

Thursday, January 09, 2014
Teva to Present at the 32nd Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Acting President & CEO will present on Tuesday, January 14, 2014 at 10:30 AM PT.   What:     Teva Presentation at the 32nd Annual J.P. Morgan Read More »

Tuesday, December 17, 2013
Teva Settles Viagra® Patent Litigation with Pfizer

JERUSALEM--(BUSINESS WIRE)--Dec. 17, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into an agreement with Pfizer Inc. to settle patent litigation related to Teva's generic version of Pfizer's Viagra® (sildenafil citrate) tablets. Under the terms of the agreement Teva will be able to launch its Abbreviated New Drug Application (ANDA) products pursuant to a royalty-bearing license on December 11, 2017, or earlier under certain circumstances. The terms Read More »

​​​